Biocept Expands U.S. Microchannel Patent Protection

Fifth issued U.S. patent covers the use of antibodies in the capture and
detection of rare cells from biological fluids with Biocept’s
microchannel capture device

SAN DIEGO–(BUSINESS WIRE)–Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company
commercializing and developing liquid biopsies to improve the detection
and treatment of cancer, announces the allowance of U.S. Patent
The patent covers the use of antibodies in the capture of cells such as
circulating tumor cells (CTCs) from blood, as well as other biological
fluids, using the company’s patented microchannel capture device.
Biocept’s antibody capture cocktail along with the microchannel are key
components of the company’s Cell Enrichment and Extraction (CEE™)
platform, providing for the high-efficiency capture, visualization and
microscopic analysis of targeted cells obtained from a patient blood
sample and used by physicians for medical decision making.

Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept, said, “The
issuance of this patent expands Biocept’s patent portfolio to include
the use of antibodies in the capture of cancer cells in combination with
our microchannel for which multiple U.S. and international patents have
been granted. Our antibody cocktail is a key part of our patented and
proprietary method to capture and analyze cells from a wide variety of
tumor types. In addition, this patent expands our IP protection for the
use of a simple blood sample, and other biological sample types, in
obtaining valuable biomarker information that can be used by physicians
to personalize treatment of individual patients.”

“We have been aggressively broadening our IP protection for our unique
methods of capturing and analyzing cancer cells in blood and other
biological fluids,” said Biocept’s President and Chief Executive
Officer, Michael Nall. “Our portfolio of U.S. and international patents
better positions Biocept to capitalize on the growing movement toward
the use of liquid biopsy, which can reduce healthcare system costs and
importantly help patients qualify for treatments that physicians can
utilize to treat their cancer.”

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that
utilizes a proprietary technology platform and a standard blood sample
to provide physicians with important prognostic and predictive
information to enhance individual treatment of patients with cancer.
Biocept’s patented technology platform captures and analyzes circulating
tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers
assays for gastric cancer, breast cancer, lung cancer, colorectal cancer
and melanoma, and plans to introduce CLIA-validated assays for prostate
cancer and other solid tumors in the near term. For additional
information, please visit

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like “may,” “will,” “should,” “could,” “expect,” “anticipate,”
“estimate,” “believe,” “intend,” or “project” or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to the use of our liquid
biopsy assays by physicians, the use of liquid biopsy generally, and the
impact of liquid biopsy on diagnostic strategies and healthcare costs,
such statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to numerous
risk factors as set forth in our Securities and Exchange Commission
(SEC) filings. The effects of such risks and uncertainties could cause
actual results to differ materially from the forward-looking statements
contained in this release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to update the
information contained in this press release except as required by law.
Readers are advised to review our filings with the SEC, which can be
accessed over the Internet at the SEC’s website located at


Jody Cain, 310-691-7100